{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:23:08Z","timestamp":1750166588640,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health and Labor Sciences Research Grants","award":["19EA1009"],"award-info":[{"award-number":["19EA1009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The Japanese Society of Medical Oncology published a guideline (GL) on febrile neutropenia (FN) in 2017. The study\u2019s purpose is to reveal how widely GL penetrated among physicians and surgeons providing chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A questionnaire survey was conducted with SurveyMonkey\u2122 for members of the Japanese Association of Supportive Care in Cancer and relevant academic organizations. Each question had four options (always do, do in more than half of patients, do in less than half, do not at all) and a free description form. Responses were analyzed with statistical text-analytics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>A total of 800 responses were retrieved. Major respondents were experts with more than 10-year experience, physicians 54%, and surgeons 46%. Eighty-seven percent of respondents knew and used GL. Forty-eight percent assessed FN with Multinational Association of Supportive Care in Cancer (MASCC) score \u201calways\u201d or \u201cmore than half.\u201d Eighty-one percent chose beta-lactam monotherapy as primary treatment in high-risk patients. Seventy-seven percent did oral antibacterial therapy in low-risk patients ambulatorily. Seventy-eight percent administered primary prophylactic G-CSF (ppG-CSF) in FN frequency\u2009\u2265\u200920% regimen. Fifty-nine percent did ppG-CSF for high-risk patients in FN frequency 10\u201320% regimen. Ninety-seven percent did not use ppG-CSF in FN frequency\u2009&lt;\u200910% regimen. The medians of complete and complete plus partial compliance rates were 46.4% (range 7.0\u201392.8) and 77.8% (range 35.4\u201398.7). The complete compliance rates were less than 30% in seven recommendations, including the MASCC score assessment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>GL is estimated to be widely utilized, but some recommendations were not followed, presumably due to a mismatch with actual clinical practices in Japan.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-021-06277-8","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T09:23:44Z","timestamp":1622798624000},"page":"6831-6839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A questionnaire survey on evaluation for penetration and compliance of the Japanese Guideline on Febrile Neutropenia among hematology-oncology physicians and surgeons"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4840-6248","authenticated-orcid":false,"given":"Nobu","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuho","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-ichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadamoto","family":"Zenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"6277_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52:427\u2013431. https:\/\/doi.org\/10.1093\/cid\/ciq147","journal-title":"Clin Infect Dis"},{"key":"6277_CR2","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ et al (2018) Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Disease Society of America Clinical Guideline Update. J Clin Oncol 36:1443\u20131453. https:\/\/doi.org\/10.1200\/JCO.2017.77.6211","journal-title":"J Clin Oncol"},{"key":"6277_CR3","unstructured":"National Comprehensive Cancer Center Network Clinical Practice Guidelines in Oncology Prevention and treatment of cancer-related infections Version 2.2020 \u2014 June 5, 2020.\u00a0https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf"},{"issue":"Suppl 5","key":"6277_CR4","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K et al (2016) Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(Suppl 5):v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"key":"6277_CR5","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00277-017-3098-3","volume":"96","author":"WJ Heinz","year":"2017","unstructured":"Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96:1775\u20131792. https:\/\/doi.org\/10.1007\/s00277-017-3098-3","journal-title":"Ann Hematol"},{"key":"6277_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jamainternmed.2013.2921","volume":"173","author":"JD Wright","year":"2013","unstructured":"Wright JD, Neugut AI, Ananth CV et al (2013) Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med 173:559\u2013568. https:\/\/doi.org\/10.1001\/jamainternmed.2013.2921","journal-title":"JAMA Intern Med"},{"key":"6277_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamainternmed.2013.2921","volume":"24","author":"CW Baugh","year":"2017","unstructured":"Baugh CW, Wang TJ, Caterino JM et al (2017) Emergency department management of patients with febrile neutropenia: guideline concordant or overly aggressive? Acad Emerg Med 24:83\u201391. https:\/\/doi.org\/10.1001\/jamainternmed.2013.2921","journal-title":"Acad Emerg Med"},{"key":"6277_CR8","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1177\/1078155219896396","volume":"26","author":"B Jansma","year":"2020","unstructured":"Jansma B, Vakkalanka P, Talan DA et al (2020) Guideline adherence for the management of emergency department patients with febrile neutropenia and no infection source: is there room for improvement? J Oncol Pharm Pract 26:1382\u20131389. https:\/\/doi.org\/10.1177\/1078155219896396","journal-title":"J Oncol Pharm Pract"},{"key":"6277_CR9","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41409-020-0811-y","volume":"55","author":"A Verlinden","year":"2020","unstructured":"Verlinden A, Mikulska M, Knelange NS et al (2020) Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplant 55:1588\u20131594. https:\/\/doi.org\/10.1038\/s41409-020-0811-y","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"6277_CR10","first-page":"137","volume":"53","author":"K Higuchi","year":"2017","unstructured":"Higuchi K (2017) A two-step approach to quantitative content analysis: KH Coder tutorial using Anne of Green Gables (Part II). Ritsumeikan Soc Sci Rev 53(1):137\u2013147","journal-title":"Ritsumeikan Soc Sci Rev"},{"key":"6277_CR11","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038\u20133051. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.3038","journal-title":"J Clin Oncol"},{"key":"6277_CR12","first-page":"237","volume":"2","author":"H Taherdoost","year":"2017","unstructured":"Taherdoost H (2017) Determining sampling size; how to calculate survey sample size. Int J Economics and Management Sys 2:237\u2013239","journal-title":"Int J Economics and Management Sys"},{"key":"6277_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.6004\/jnccn.2017.7038","volume":"15","author":"GH Lyman","year":"2017","unstructured":"Lyman GH, Poniewierski MS (2017) A patient risk model of chemotherapy-induced febrile neutropenia: lessons learned from the ANC Study Group. J Natl Compr Canc Netw 15:1543\u20131550. https:\/\/doi.org\/10.6004\/jnccn.2017.7038","journal-title":"J Natl Compr Canc Netw"},{"key":"6277_CR14","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475\u20132484. https:\/\/doi.org\/10.1093\/annonc\/mdt226","journal-title":"Ann Oncol"},{"key":"6277_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s13187-019-01638-8","volume":"35","author":"A Hawkins","year":"2020","unstructured":"Hawkins A, Murphy A, McNamara M et al (2020) A survey of oncologists\u2019 perceptions and opinions regarding the use of Granulocyte Colony-Stimulating Factors. J Cancer Educ 35:178\u2013186. https:\/\/doi.org\/10.1007\/s13187-019-01638-8","journal-title":"J Cancer Educ"},{"key":"6277_CR16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00520-013-2021-2","volume":"22","author":"K Kremieniecki","year":"2014","unstructured":"Kremieniecki K, Sevelda P, Erdkamp E et al (2014) Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumors receiving myelotoxic chemotherapy-findings from clinical practice. Support Care Cancer 22:667\u2013677. https:\/\/doi.org\/10.1007\/s00520-013-2021-2","journal-title":"Support Care Cancer"},{"key":"6277_CR17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00520-018-4399-3","volume":"27","author":"F van Ryckeghem","year":"2019","unstructured":"van Ryckeghem F, Haverbeke C, Wynendaele W et al (2019) Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study. Support Care Cancer 27:1099\u20131108. https:\/\/doi.org\/10.1007\/s00520-018-4399-3","journal-title":"Support Care Cancer"},{"key":"6277_CR18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00520-018-4481-x","volume":"27","author":"H Link","year":"2018","unstructured":"Link H, Kerkmann M, Holtmann L et al (2018) G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer 27:1459\u20131469. https:\/\/doi.org\/10.1007\/s00520-018-4481-x","journal-title":"Support Care Cancer"},{"key":"6277_CR19","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s00520-017-3572-4","volume":"25","author":"C Bokemeyer","year":"2017","unstructured":"Bokemeyer C, Gasc\u00f3n P, Aapro M et al (2017) Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. Support Care Cancer 25:1819\u20131828. https:\/\/doi.org\/10.1007\/s00520-017-3572-4","journal-title":"Support Care Cancer"},{"key":"6277_CR20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/1471-2407-10-642","volume":"10","author":"L Gerlier","year":"2010","unstructured":"Gerlier L, Lamotte M, Awada A et al (2010) The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin\u2019s lymphoma. BMC Cancer 10:642. https:\/\/doi.org\/10.1186\/1471-2407-10-642","journal-title":"BMC Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06277-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06277-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06277-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T08:15:19Z","timestamp":1632557719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06277-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["6277"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06277-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"14 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is not required to be reviewed by an ethical committee because it is designed as a questionnaire to doctors about the daily clinical practice on GL, and respondents voluntarily answered the questions on the website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}